|
|
|
Department of Pharmaceutical Sciences, School of Pharmacy, and University of Colorado Cancer Center, University of Colorado-Denver, Aurora, Colorado. Constitutive activation of phosphoinositide 3-kinase (PI3K)-Akt pathway...
On 11/2/09, Dendreon (NASDAQ: DNDN) announced that it has completed the submission of its amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant...
By DAVID ROGERS Daily News Staff Writer Friday, November 20, 2009 It's like having to pick between front-row seats to shows by Karl Lagerfeld or Giorgio Armani. The events even start at the same time, 6 p.m. Three Cleveland...
To the editor, Men across the province are sprouting facial hair in support of men's health, a tradition that started six years ago in Australia when a couple of guys wanted to bring back the moustache as a statement to raise...
Women worried about breast cancer have just one concern: What can they do to reduce the risk of dying from the disease? Those are the issues a key medical advisory committee sought to address with the release of new breast...
U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal...
OBJECTIVE. The purpose of this study was to compare apparent diffusion coefficients, metabolic ratios, and vascularity values within histologically defined prostate tumors with those in nontumor tissue to determine which...
By Katherine McIntire Peters kpeters@govexec.com November 19, 2009 The Nuclear Regulatory Commission on Nov. 17 found the Philadelphia Veterans Affairs Medical Center in violation of multiple regulations regarding the surgical...
If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment options, because prostate cancer is not very sensitive to cytostatic agents. Temozolomide (TMZ) as an orally applicable...
REDWOOD CITY, Calif., Nov. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results...
